Publicaciones (48) Publicaciones de Ana Alfonso Piérola

2024

  1. Myelodysplastic neoplasms

    Medicina Clinica, Vol. 162, Núm. 2, pp. 77-82

  2. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

2023

  1. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study

    The Lancet Haematology, Vol. 10, Núm. 2, pp. e117-e128

  2. CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

    Hematology, Transfusion and Cell Therapy, Vol. 45, Núm. 2, pp. 266-274

  3. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  4. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

  5. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

  6. Severe laryngeal edema after CAR-T cell treatment in a patient with multiple myeloma: a case report

    Clinical Case Reports, Vol. 11, Núm. 6, pp. e7281

  7. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  3. Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes

    Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235

  4. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

  5. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

  6. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

    Frontiers in Oncology, Vol. 12

  7. Updates on the Management of Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 19

2021

  1. Current therapy of the patients with mds: Walking towards personalized therapy

    Journal of Clinical Medicine, Vol. 10, Núm. 10

  2. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Leukemia, Vol. 35, Núm. 12, pp. 3542-3550

2020

  1. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

    PLoS ONE, Vol. 15, Núm. 1

  2. Car t-cells in multiple myeloma are ready for prime time

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-16